Revolution Medicines, Inc. $RVMD Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group cut its Revolution Medicines position by 65% in the second quarter, selling 1.23 million shares and retaining 659,279 shares worth approximately $123.5 million.
• Institutional ownership remains high at 94.34%, while several funds—including Handelsbanken Fonder, Bank of New York Mellon and Assenagon—added or initiated positions.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $198.89, despite shares trading near recent highs and the company reporting a larger-than-expected quarterly loss of $3.06 per share.

Alyeska Investment Group L.P. reduced its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 65.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 659,279 shares of the company's stock after selling 1,226,542 shares during the quarter. Alyeska Investment Group L.P. owned about 0.31% of Revolution Medicines worth $123,470,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. State of Wyoming acquired a new position in Revolution Medicines in the 2nd quarter valued at about $1,769,000. Handelsbanken Fonder AB grew its holdings in shares of Revolution Medicines by 243.6% during the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company's stock worth $39,755,000 after buying an additional 150,500 shares in the last quarter. Eagle Health Investments LP purchased a new stake in shares of Revolution Medicines during the fourth quarter worth about $9,231,000. Assenagon Asset Management S.A. acquired a new position in shares of Revolution Medicines in the second quarter valued at approximately $37,547,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Revolution Medicines in the second quarter valued at approximately $112,566,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RVMD shares. Wedbush raised their price objective on Revolution Medicines from $201.00 to $225.00 and gave the stock an "outperform" rating in a report on Thursday. Oppenheimer upped their target price on Revolution Medicines from $230.00 to $260.00 and gave the company an "outperform" rating in a research note on Thursday. Evercore reiterated an "outperform" rating and set a $320.00 target price on shares of Revolution Medicines in a research report on Thursday. Mizuho lifted their price target on Revolution Medicines from $185.00 to $215.00 and gave the company an "outperform" rating in a report on Monday, July 6th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $248.00 price target on shares of Revolution Medicines in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has a consensus rating of "Moderate Buy" and an average price target of $198.89.

Revolution Medicines Trading Down 6.0%

RVMD opened at $207.88 on Friday. The firm's 50 day moving average is $193.33 and its 200-day moving average is $148.59. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $44.56 billion, a P/E ratio of -23.57 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period last year, the business posted ($1.31) earnings per share. Analysts expect that Revolution Medicines, Inc. will post -8.85 EPS for the current fiscal year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Insider Activity at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,175 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the transaction, the insider owned 291,876 shares of the company's stock, valued at $45,567,681.12. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of the company's stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares of the company's stock, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source